NovoCure

Central African Republic
Bayanga, Sangha-Mbaéré, Central African Republic

Company profile

NovoCure company profile

Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.

Business identity

Contact email
[email protected]
Phone number
+1 603 436 2809
Operating status
Active
Company type
For Profit
Employee range
1,001-5,000 employees
Revenue range
$500,000+
Founded
2000-01-01, Year

Headquarters

Country code
CF
Continent
Africa

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$13M
Last funding
Post IPO Debt / $100M / 2024-05-02
Last equity funding
Post IPO Equity / $13M
Investors
8
Lead investors
3
Founders
2
Articles
250
Exited on
2015-10-02

Founders and investors

Founders

William F. DoyleYoram Palti

Lead investors

BioPharma CreditJP Morgan ChasePharmakon Advisors

Investors

Index VenturesJohnson & Johnson Development CorporationJP Morgan ChasePfizerPfizer Venture Investments